Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

Pitocin

×

Overview

What is Pitocin?

Oxytocin injection USP is a sterile, clear, colorless aqueous solution of synthetic oxytocin, for intravenous infusion or intramuscular injection. Oxytoxin is a nonapeptide found in pituitary extracts from mammals. It is standardized to contain 10 units of oxytocic hormone/mL and contains 0.5% Chlorobutanol, a chloroform derivative as a preservative, with the pH adjusted with acetic acid. Oxytocin may contain up to 16% of total impurities. The hormone is prepared synthetically to avoid possible contamination with vasopressin (ADH) and other small polypeptides with biologic activity. Oxytocin has the empirical formula CHNOS (molecular weight 1007.19). The structural formula is as follows:



What does Pitocin look like?



What are the available doses of Pitocin?

Sorry No records found.

What should I talk to my health care provider before I take Pitocin?

Sorry No records found

How should I use Pitocin?

Elective induction of labor is defined as the initiation of labor in a pregnant individual who has no medical indications for induction. Since the available data are inadequate to evaluate the benefits-to-risks considerations, oxytocin is not indicated for elective induction of labor.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.

The dosage of oxytocin is determined by the uterine response and must therefore be individualized and initiated at a very low level. The following dosage information is based upon various regimens and indications in general use.


What interacts with Pitocin?


  • Antepartum use of oxytocin is contraindicated in any of the following circumstances:

    • Where there is significant cephalopelvic disproportion;
    • In unfavorable fetal positions or presentations, such as transverse lies, which are undeliverable without conversion prior to delivery;
    • In obstetrical emergencies where the benefit-torisk ratio for either the fetus or the mother favors surgical intervention;
    • In fetal distress where delivery is not imminent;
    • Where adequate uterine activity fails to achieve satisfactory progress;
    • Where the uterus is already hyperactive or hypertonic;
    • In cases where vaginal delivery is contraindicated, such as invasive cervical carcinoma, active herpes genitalis, total placenta previa, vasa previa, and cord presentation or prolapse of the cord;
    • In patients with hypersensitivity to the drug.



What are the warnings of Pitocin?

Central nervous system side effects including light headedness, dizziness, or vertigo have been reported with minocycline therapy. Patients who experience these symptoms should be cautioned about driving vehicles or using hazardous machinery while on minocycline therapy. These symptoms may disappear during therapy and usually disappear rapidly when the drug is discontinued.


What are the precautions of Pitocin?

General













              Drug Interactions

              Severe hypertension has been reported when oxytocin was given three to four hours following prophylactic administration of a vasoconstrictor in conjunction with caudal block anesthesia. Cyclopropane anesthesia may modify oxytocin’s cardiovascular effects, so as to produce unexpected results such as hypotension. Maternal sinus bradycardia with abnormal atrioventricular rhythms has also been noted when oxytocin was used concomitantly with cyclopropane anesthesia.

              Carcinogenesis, Mutagenesis, Impairment of Fertility

              There are no animal or human studies on the carcinogenicity and mutagenicity of this drug, nor is there any information on its effect on fertility.

              Pregnancy

              Animal reproduction studies have not been conducted with oxytocin. There are no known indications for use in the first trimester of pregnancy other than in relation to spontaneous or induced abortion. Based on the wide experience with this drug and its chemical structure and pharmacological properties, it would not be expected to present a risk of fetal abnormalities when used as indicated.

              See in the fetus or neonate.

              See section.


              What are the side effects of Pitocin?

              The following adverse reactions have been reported in the mother:

              Excessive dosage or hypersensitivity to the drug may result in uterine hypertonicity, spasm, tetanic contraction, or rupture of the uterus.

              The possibility of increased blood loss and afibrinogenemia should be kept in mind when administering the drug.

              Severe water intoxication with convulsions and coma has occurred, associated with a slow oxytocin infusion over a 24-hour period. Maternal death due to oxytocininduced water intoxication has been reported.

              The following adverse reactions have been reported in the fetus or neonate:


              What should I look out for while using Pitocin?

              Antepartum use of oxytocin is contraindicated in any of the following circumstances:

              Oxytocin, when given for induction of labor or augmentation of uterine activity, should be administered only by the intravenous route and with adequate medical supervision in a hospital.


              What might happen if I take too much Pitocin?

              Overdosage with oxytocin depends essentially on uterine hyperactivity whether or not due to hypersensitivity to this agent. Hyperstimula-tion with strong (hypertonic) or prolonged (tetanic) contractions, or a resting tone of 15 to 20 mm HO or more between contractions can lead to tumultuous labor, uterine rupture, cervical and vaginal lacerations, postpartum hemorrhage, uteroplacental hypoperfusion, and variable deceleration of fetal heart, fetal hypoxia, hypercapnia, perinatal hepatic necrosis or death. Water intoxication with convulsions, which is caused by the inherent antidiuretic effect of oxytocin, is a serious complication that may occur if large doses (40 to 50 milliunits/minute) are infused for long periods. Management consists of immediate discontinuation of oxytocin and symptomatic and supportive therapy.


              How should I store and handle Pitocin?

              Store the kit at 2°-8°C (36°-46°F) and protect from light.ArrayStore the kit at 2°-8°C (36°-46°F) and protect from light.ArrayOxytocin Injection USP Synthetic is available as follows: NDC 0591-3553-69 Packages of twenty-five oversized 1-mL vials, each containing 10 units of oxytocin.


              ×

              Clinical Information

              Chemical Structure

              No Image found
              Clinical Pharmacology

              Uterine motility depends on the formation of the contractile protein actomyosin under the influence of the Ca-dependent phosphorylating enzyme myosin light-chain kinase. Oxytocin promotes contractions by increasing the intracellular Ca. Oxytocin has specific receptors in the myometrium and the receptor concentration increases greatly during pregnancy, reaching a maximum in early labor at term. The response to a given dose of oxytocin is very individualized and depends on the sensitivity of the uterus, which is determined by the oxytocin receptor concentration. However, the physician should be aware of the fact that oxytocin even in its pure form has inherent pressor and antidiuretic properties which may become manifest when large doses are administered. These properties are thought to be due to the fact that oxytocin and vasopressin differ in regard to only two of the eight amino acids (see section).

              Oxytocin is distributed throughout the extracellular fluid. Small amounts of the drug probably reach the fetal circulation. Oxytocin has a plasma half-life of about 1 to 6 minutes which is decreased in late pregnancy and during lactation. Following intravenous administration of oxytocin, uterine response occurs almost immediately and subsides within 1 hour. Following intramuscular injection of the drug, uterine response occurs within 3 to 5 minutes and persists for 2 to 3 hours. Its rapid removal from plasma is accomplished largely by the kidney and the liver. Only small amounts are excreted in urine unchanged.

              Non-Clinical Toxicology
              Antepartum use of oxytocin is contraindicated in any of the following circumstances:

              Oxytocin, when given for induction of labor or augmentation of uterine activity, should be administered only by the intravenous route and with adequate medical supervision in a hospital.

              Severe hypertension has been reported when oxytocin was given three to four hours following prophylactic administration of a vasoconstrictor in conjunction with caudal block anesthesia. Cyclopropane anesthesia may modify oxytocin’s cardiovascular effects, so as to produce unexpected results such as hypotension. Maternal sinus bradycardia with abnormal atrioventricular rhythms has also been noted when oxytocin was used concomitantly with cyclopropane anesthesia.

              The following adverse reactions have been reported in the mother:

              Excessive dosage or hypersensitivity to the drug may result in uterine hypertonicity, spasm, tetanic contraction, or rupture of the uterus.

              The possibility of increased blood loss and afibrinogenemia should be kept in mind when administering the drug.

              Severe water intoxication with convulsions and coma has occurred, associated with a slow oxytocin infusion over a 24-hour period. Maternal death due to oxytocininduced water intoxication has been reported.

              The following adverse reactions have been reported in the fetus or neonate:

              ×

              Reference

              This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
              "https://dailymed.nlm.nih.gov/dailymed/"

              While we update our database periodically, we cannot guarantee it is always updated to the latest version.

              ×

              Review

              Rate this treatment and share your opinion


              Helpful tips to write a good review:

              1. Only share your first hand experience as a consumer or a care giver.
              2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
              3. Fill in the optional information to help other users benefit from your review.

              Reason for Taking This Treatment

              (required)

              Click the stars to rate this treatment

              This medication has worked for me.




              This medication has been easy for me to use.




              Overall, I have been satisfied with my experience.




              Write a brief description of your experience with this treatment:

              2000 characters remaining

              Optional Information

              Help others benefit from your review by filling in the information below.
              I am a:
              Gender:
              ×

              Professional

              Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
              ×

              Tips

              Tips

              ×

              Interactions

              Interactions

              A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).